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1. BACKGROUND {#mgg3362-sec-0005}
=============

Neurotransmission in the central nervous system depends on synaptic vesicle transport. Neurotransmitters are taken up by exocytotic vesicles which fuse with the plasma membrane, releasing neurotransmitters into the synapse (Sudhof, [2004](#mgg3362-bib-0013){ref-type="ref"}). Neurotransmitters in the synapse are degraded or taken up into the presynaptic axon. Vesicle endocytosis, when vesicles bud off from the plasma membrane into the presynaptic axon, is mediated by proteins including amphysin, endophilin, clathrin, and dynamin (Rizzoli, [2014](#mgg3362-bib-0011){ref-type="ref"}). Newly synthesized or retrieved neurotransmitters enter these new vesicles and restart the cycle (Takei, [1996](#mgg3362-bib-0014){ref-type="ref"}).

The Dynamin family of proteins interact with clathrin in the vesicle budding cycle and participate in the scission between the cell membrane and vesicle wall. After the invagination of the lipid membrane, dynamin binds GTP and its alpha helixes wrap around and pinch the budding vesicle. Next, dynamin uses the energy from GTP hydrolysis to sever the membrane tubules and complete vesicle fission (Antonny et al., [2016](#mgg3362-bib-0003){ref-type="ref"}). This process is critical for the synaptic vesicle cycle (McNiven, [2000](#mgg3362-bib-0009){ref-type="ref"}). Dynamin proteins have five domains; the GTPase domain is the largest and best understood, followed by a middle domain, pleckstrin homology (PH) domain, coiled coil (CC) domain, and a proline‐rich domain (PRD) (McNiven, [2000](#mgg3362-bib-0009){ref-type="ref"}). The PH domain is thought to interact directly with the lipid bilayer (Vallis, Wigge, Marks, Evans, & McMahon, [1999](#mgg3362-bib-0015){ref-type="ref"}).

The *DNM1* gene (MIM 602377) codes for dynamin 1 and is mainly expressed in the central nervous system (Romeu & Arola, [2014](#mgg3362-bib-0012){ref-type="ref"}). Pathogenic *DNM1* variants affect brain development and function and cause epileptic encephalopathy associated with global developmental delay (DD) (Allen et al., [2016](#mgg3362-bib-0002){ref-type="ref"}; Deng et al., [2016](#mgg3362-bib-0004){ref-type="ref"}; Epi4K Consortium; Epilepsy Phenome/Genome Project, [2013](#mgg3362-bib-0006){ref-type="ref"}; Euro E‐RESC, EpilepsyPhenome/Genome P, Epi4K Constorium, [2014](#mgg3362-bib-0007){ref-type="ref"}; Nakashima et al., [2016](#mgg3362-bib-0010){ref-type="ref"}). Previously reported patients with *DNM1*‐related disorder carry pathogenic variants in the GTPase or middle domains, but never in the PH domain (Allen et al., [2016](#mgg3362-bib-0002){ref-type="ref"}; Deng et al., [2016](#mgg3362-bib-0004){ref-type="ref"}; Epi4K Consortium; Epilepsy Phenome/Genome Project, [2013](#mgg3362-bib-0006){ref-type="ref"}; Euro E‐RESC, EpilepsyPhenome/Genome P, Epi4K Constorium, [2014](#mgg3362-bib-0007){ref-type="ref"}; Nakashima et al., [2016](#mgg3362-bib-0010){ref-type="ref"}).

Here, we report 8‐year‐old identical twin sisters with a de novo p.Lys535Glu likely pathogenic novel variant in exon 15 of *DNM1* (NM_004408.3), the first documented pathogenic variant in the PH domain. Although all previously reported patients with *DNM1* pathogenic variants exhibited epileptic encephalopathy and severe neurological phenotype, the two probands in this report had no seizures and exhibited mild to moderate DD/intellectual disability (ID) and autism spectrum disorder. Our data suggest an emerging and previously undescribed phenotype associated with a specific *DNM1* missense genetic variant in the PH domain.

2. CLINICAL REPORT {#mgg3362-sec-0006}
==================

Patients 1 and 2 are monozygotic triplet sisters who presented for evaluation of DD, autism spectrum disorder, some dysmorphic features, and hypotonia. They were born at 36 weeks gestation, which was conceived naturally, via an uncomplicated cesarian section secondary to triplet pregnancy. There were no complications after delivery. They have a healthy triplet brother. Patient 1 had a birth weight of 2.8 kg (\>97th percentile for triplet gestation), a birth length of 49 cm (\>97th percentile), and an occipitofrontal circumference (OFC) of 33.8 cm (80th percentile). Patient 2 had a birth weight of 2.55 kg (50th--90th percentile for triplet gestation), a birth length of 48.2 cm (\>97th centile), and OFC of 33.1 cm (65th percentile). Their triplet brother had a birth weight of 2.38 kg (50th--90th percentile for triplet gestation), a birth length of 46.9 cm (97th percentile), and OFC of 32 cm (40th percentile).

Developmental concerns were first noted at 4 months of age when both sisters were noted to lack visual tracking, but this spontaneously resolved at 7 months of age. Patient 1 and 2 started receiving physical, occupational, and speech therapies at 1 year of age due to delayed speech and motor milestones. Both sisters started sitting at 7--8 months, crawling at 11 months, and walking at 18 months. At 18 months, Patient 1 could say 5--10 words, but lost most of this vocabulary by age 2. Patient 2 had delayed language acquisition but no language loss. Their triplet brother started sitting at 6 months, crawling at 9 months and walking at 15 months. He required speech therapy for 9 months during third year of life for mild speech delay. The brother is in mainstream classes, never required any resources at school, and does not exhibit neurobehavioral abnormalities. The sisters were diagnosed with autism at 3 years of age and have been receiving applied behavior analysis (ABA) therapy since. At the age of 5, Patient 2 had one episode of febrile seizure. She had a normal brain MRI after this event. She also had a few staring episodes, but her EEG at 7 years of age was normal.

Developmental evaluation of both sisters at age 8 years revealed that Patient 1 can say 15 words but rarely speaks. She can add and subtract double digits, recognize sight words, and use a few signs. She sometimes becomes agitated and may bite or hit herself or others. Patient 2 can use 50 words, combine 2--3 words, use many signs, write her name, recognize some sight words, and complete some basic addition and subtraction. She occasionally becomes agitated, may hit herself or others, and refuses to cooperate with therapy or schoolwork. Patient 2 receives Ritalin and Clonidine for behavioral problems. A formal neuropsychological assessment was performed at 8 years of age for both sisters and the detailed results are provided in Appendix [S1](#mgg3362-sup-0001){ref-type="supplementary-material"}.

On physical exam at 8 years, Patient 1 and 2 had no major dysmorphic features but were each noted to have a broad forehead, smooth philtrum, widely spaced teeth, high‐arched palate, and mild retrognathia (Figure [1](#mgg3362-fig-0001){ref-type="fig"}a,b). Their neurological exam revealed mild axial and appendicular hypotonia and drooling. Patient 1\'s weight was 24 kg (24th centile), height was 126.6 cm (28th centile) and OFC was 53.3 cm (85th centile). Patient 2\'s weight was 24.7 kg (30th centile), height was 125.4 cm (22nd centile) and OFC was 54.3 cm (95th centile).

![Facial features of Patient 1 & 2 and their brother. Note broad forehead, smooth philtrum, widely spaced teeth and mild retrognathia in proband 1 (a) and proband 2 (b). The brother (c) exhibits no dysmorphic features except for mild hypertelorism](MGG3-6-294-g001){#mgg3362-fig-0001}

The genetic workup of the Patient 1 and 2 started at 3 years of age and included normal karyotype, chromosomal microarray analysis, and fragile X testing. Because of muscle weakness and elevated blood lactate, the two sisters were diagnosed with a nonspecific mitochondrial disease. However, mtDNA sequencing and deletion/duplication studies and a mitochondrial nuclear gene panel were normal except for a variant of unknown significance, p.Asp85Asn, in *KCNE1*. This finding prompted a cardiology consultation and both sisters had a normal echocardiogram and EKG. The exome results (see below) prompted an electroencephalogram which was normal in both sisters.

3. MATERIALS AND METHODS {#mgg3362-sec-0007}
========================

The Institutional Review Board of Washington University School of Medicine approved our study protocol and informed consent was obtained from the parents for publication of genetic results and photographs. Clinical whole‐exome sequencing was performed using a trio design with one of the identical twin sisters submitted as a proband and the second sibling and their parents used for segregation analysis. For more details see Appendix [S2](#mgg3362-sup-0001){ref-type="supplementary-material"}.

4. MOLECULAR RESULTS {#mgg3362-sec-0008}
====================

Exome sequencing of the sisters identified a de novo, heterozygous, likely pathogenic variant designated as c.1603A\>G (p.Lys535Glu) in *DNM1*. This variant has not been observed in approximately 6,500 individuals that were sequenced as part of the National Heart, Lung, and Blood Institute (NHLBI) exome sequence project or in ExAC database (<http://exac.broadinstitute.org/>). Both parents tested negative for this variant.

5. DISCUSSION {#mgg3362-sec-0009}
=============

Pathogenic variants in *DNM1* have been reported in association with early‐onset epileptic encephalopathy (including West and Lennox‐Gastaut syndromes), intractable seizures starting within the first year of life, motor impairments, and severe to profound ID (Allen et al., [2016](#mgg3362-bib-0002){ref-type="ref"}; Deng et al., [2016](#mgg3362-bib-0004){ref-type="ref"}; Epi4K Consortium; Epilepsy Phenome/Genome Project, [2013](#mgg3362-bib-0006){ref-type="ref"}; Euro E‐RESC, EpilepsyPhenome/Genome P, Epi4K Constorium, [2014](#mgg3362-bib-0007){ref-type="ref"}; Nakashima et al., [2016](#mgg3362-bib-0010){ref-type="ref"}) (Table [1](#mgg3362-tbl-0001){ref-type="table-wrap"}). Other rare clinical features reported in some individuals include hypotonia, developmental regression, movement disorder, autism, cortical visual impairment, behavioral concerns, and microcephaly (Allen et al., [2016](#mgg3362-bib-0002){ref-type="ref"}; Deng et al., [2016](#mgg3362-bib-0004){ref-type="ref"}; Epi4K Consortium; Epilepsy Phenome/Genome Project, [2013](#mgg3362-bib-0006){ref-type="ref"}; Euro E‐RESC, EpilepsyPhenome/Genome P, Epi4K Constorium, [2014](#mgg3362-bib-0007){ref-type="ref"}; Nakashima et al., [2016](#mgg3362-bib-0010){ref-type="ref"}) (Table [1](#mgg3362-tbl-0001){ref-type="table-wrap"}). The two patients described here exhibit a milder phenotype with mild to moderate ID, autistic symptoms, and other than a single febrile seizure in Patient 2, no history of seizures.

###### 

Clinical and genetic characteristics of patient with DNM1‐related disorder

  Individual (reference)                      Case 1 (Nakashima et al., [2016](#mgg3362-bib-0010){ref-type="ref"})        Case 2 (Euro E‐RESC, Epilepsy Phenome/Genome P, Epi4K Constorium, [2014](#mgg3362-bib-0007){ref-type="ref"})   Case 3 (Deng et al., [2016](#mgg3362-bib-0004){ref-type="ref"})                       Case 4 (Euro E‐RESC, Epilepsy Phenome/Genome P, Epi4K Constorium, [2014](#mgg3362-bib-0007){ref-type="ref"})   Case 5 (Euro E‐RESC, Epilepsy Phenome/Genome P, Epi4K Constorium, [2014](#mgg3362-bib-0007){ref-type="ref"})   Case 6 (Euro E‐RESC, Epilepsy Phenome/Genome P, Epi4K Constorium, [2014](#mgg3362-bib-0007){ref-type="ref"})       Case 7 (Nakashima et al., [2016](#mgg3362-bib-0010){ref-type="ref"})             Case 8 (Allen et al., [2016](#mgg3362-bib-0002){ref-type="ref"})   Case 9 (Euro E‐RESC, Epilepsy Phenome/Genome P, Epi4K Constorium, [2014](#mgg3362-bib-0007){ref-type="ref"})   Case 10 (Epi4K Consortium; Epilepsy Phenome/Genome Project, [2013](#mgg3362-bib-0006){ref-type="ref"})   Proband 1                                                                                      Proband 2
  ------------------------------------------- --------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------ -------------------------------------------------------------------------------- ------------------------------------------------------------------ -------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------
  Domain involved                             GTPase                                                                      GTPase                                                                                                         GTPase                                                                                GTPase                                                                                                         GTPase                                                                                                         GTPase                                                                                                             GTPase                                                                           GTPase                                                             Middle                                                                                                         Middle                                                                                                   PH                                                                                             PH
  Mutation                                    c.127G\>A (p.Gly43Ser)                                                      c.194C\>A (p.Thr65Asn)                                                                                         c\. 443A\>G (p.Glu148Arg)                                                             c.529G\>C (p.Ala177Pro)                                                                                        c.618G\>C (p.Lys206Asn)                                                                                        c.709C\>T (p.Arg237Trp)                                                                                            c.709C\>T (p.Arg237Trp)                                                          c.865A\>T (p.Ile289Phe)                                            c.1076G\>C (p.Gly359Ala)                                                                                       c.1190G\>A (p.Gly397Asp)                                                                                 c.1603A\>G (p.Lys535Glu)                                                                       c.1603A\>G (p.Lys535Glu)
  Gender, age (years)                         M, 15                                                                       M, 6                                                                                                           M, 5                                                                                  F, 15                                                                                                          M, 8                                                                                                           F, 13                                                                                                              M, 6                                                                             M, N/A                                                             M, 6                                                                                                           M, N/A                                                                                                   F, 8                                                                                           F, 8
  Diagnosis                                   LGS                                                                         Infantile spasms                                                                                               Infantile spasms                                                                      LGS                                                                                                            Infantile spasms                                                                                               Infantile spasms                                                                                                   West syndrome                                                                    Infantile spasms                                                   LGS                                                                                                            Infantile spasms                                                                                         Autism, DD                                                                                     Autism, DD
  Development prior to seizure onset          Global DD                                                                   Global DD                                                                                                      Some DD                                                                               Probably normal                                                                                                Some DD noted                                                                                                  Global DD                                                                                                          Global DD                                                                        Normal                                                             Normal                                                                                                         N/A                                                                                                      N/A                                                                                            N/A
  Seizure onset (months)                      11                                                                          13                                                                                                             7                                                                                     7                                                                                                              6                                                                                                              12                                                                                                                 10                                                                               2                                                                  2                                                                                                              Infancy                                                                                                  N/A                                                                                            N/A
  Seizure type at onset                       Neck anteflexion, rolling of the eyes and elevating upper limbs             Epileptic spasms                                                                                               Twitches: Nodded, shrugged, strangled                                                 Epileptic spasms                                                                                               Epileptic spasms                                                                                               Epileptic spasms                                                                                                   Atonic type with head dropping                                                   Nodded, slightly ocular myoclonus                                  Epileptic spasms                                                                                               N/A                                                                                                      N/A                                                                                            N/A
  Other seizure types/course of seizures      Atonic and tonic seizures, myoclonic seizure                                Atypical absences, tonic, focal dyscognitive seizures, obtundation status                                                                                                                            Atypical absences with eyelid fluttering, drop attacks, generalized tonic clonic seizures                      Atonic and tonic seizures                                                                                      Myoclonic, atypical absences, focal dyscognitive seizures, generalized tonic clonic seizures, obtundation status   Absences                                                                         N/A                                                                Seizure‐free since age 3.5 years                                                                               N/A                                                                                                      N/A                                                                                            Age 5, one episode of unresponsiveness and eye deviation to the left side, characterized by some back arching and leaning over to the left side
  EEG at onset of seizures                    Partial hypsarrhythmia                                                      Hypsarrhythmia                                                                                                 Sharp wave, slow wave                                                                 Slow background, multifocal discharges                                                                         Hypsarrhythmia                                                                                                 Modified hypsarrhythmia                                                                                            Multiple epileptic activity with disorganization of basal activity               Multi -- focal epileptic discharge                                 High voltage bilateral slow spike‐wave discharges                                                              N/A                                                                                                      Normal                                                                                         Normal
  Neurological Findings                       N/A                                                                         Axial hypotonia                                                                                                Axial hypotonia                                                                       Mild diffuse hypotonia, mild ataxia with wide based gait, mild tremor                                          General hypotonia                                                                                              Axial hypotonia, secondary microcephaly                                                                            General hypotonia, choric and movements and distal limb dystonia, microcephaly   Deformity, movement disorders                                      General hypotonia                                                                                              N/A                                                                                                      Hypotonia                                                                                      Hypotonia
  Brain Imaging/MRI                           Normal                                                                      Generalized cerebral atrophy                                                                                   Left ventricle slightly widened                                                       Normal                                                                                                         Normal                                                                                                         Generalized cerebral atrophy                                                                                       Arachnoid cyst in right temporal lobe                                            Myelin dysplasia                                                   Normal                                                                                                         N/A                                                                                                      N/A                                                                                            Normal
  Response to treatment/antiepileptic drugs   Intractable, seizure free from 3 to 5 years old with VPA and CLB            Intractable                                                                                                    Intractable, seizure free 4 years old 5 months to 5 years old 5 months age with VPA   Intractable, seizure free from 3 to 8 years of age with VPA and VGB                                            Intractable, some response to ketogenic diet                                                                   Intractable                                                                                                        Intractable                                                                      Intractable                                                        Seizure‐free on ketogenic diet                                                                                 N/A                                                                                                      N/A                                                                                            N/A
  Intellectual Disability                     Severe                                                                      Profound                                                                                                       Severe                                                                                Severe                                                                                                         Severe                                                                                                         Profound                                                                                                           Severe                                                                           Profound                                                           Severe                                                                                                         N/A                                                                                                      Mild‐moderate                                                                                  Mild‐moderate
  Development at last follow up               Sit and walk without support; no speech; temporary self‐ harming behavior   No speech; no visual fixation; does not sit or walk                                                            Erect instability, sit alone instability, no language, cannot walk                    No speech; autism spectrum disorder; behavioral problems with self‐harm behavior                               No speech; does not walk                                                                                       No speech; no visual fixation; does not sit or walk                                                                Sit and walk without support; no speech                                          N/A                                                                No speech; does not walk; behavioral problems with self‐ harming behavior                                      N/A                                                                                                      Sit and walk without support; minimal speech; behavioral problems with self‐harming behavior   Sit and walk without support; limited speech; behavioral problems with self‐harming behavior

CLB, clobazam; DD, developmental delay; F, female; LGS, Lennox Gastaut syndrome; M, male; N/A, not available or applicable; VGB, vigabatrin; VPA, valproic acid.
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The twin sisters studied here share the de novo variant, c.1603A\>G (p.Lys535Glu) in exon 15 of *DNM1*, classified as likely pathogenic. This variant has not previously been reported in patients or databases of healthy controls. It is a nonconservative amino acid substitution that occurs at an evolutionary conserved position (Figure [S1](#mgg3362-sup-0001){ref-type="supplementary-material"}). Previous in vitro studies presented below further support the variant\'s pathogenicity.

Eight previously reported patients with DNM1‐related disorder carry pathogenic variants in the GTPase domain and two carry variants in the middle domain (Figure [2](#mgg3362-fig-0002){ref-type="fig"}a). To our knowledge, the monozygotic twin sisters in this study have the first reported PH likely pathogenic variant. Our report indicates this variant in the PH domain causes less functional impairments and leads to a less severe phenotype than variants in the GTPase or middle domains.

![(a) Exons 1--23 of *DNM1*, based on transcript DNM1‐009 (ENST00000341179.11). The genetic variant described in this paper and previously reported pathogenic variants are shown in the diagram. The 5 important Dynamin 1 domains are depicted. (b) Diagram of the four common DNM1 isoforms (RefSeq: NM_004408.3, UniProt: Q05193; dark blue rectangles). Numbers refer to amino acids. The main protein isoform is \#1 and has 864 amino acids. Light blue rectangles indicate different amino acids compared to isoform 1. All *DNM1* variants are shown in relation to the different isoforms](MGG3-6-294-g002){#mgg3362-fig-0002}

Dynamin is a family of proteins with GTPase activity that facilitate vesicle scission (Achiriloaie, Barylko, & Albanesi, [1999](#mgg3362-bib-0001){ref-type="ref"}). In vitro studies showed that the expression of certain GTPase mutants decreased endocytosis activity by interfering with vesicle scission during synaptic vesicle endocytosis and a middle domain mutation disrupted higher order DNM1 oligomerization (Dhindsa et al., [2015](#mgg3362-bib-0005){ref-type="ref"}). Experiments also showed that when residue 44 in the GTPase domain of *DNM1* was mutated, the protein had reduced binding affinity for GTP and reduced fission activity (Lee, Frank, Marks, & Lemmon, [1999](#mgg3362-bib-0008){ref-type="ref"}).

The PH domain is primarily responsible for binding PIP2, yet the PH loop has been suggested to have constrictive functioning in the oligomer helix (Achiriloaie, Barylko, & Albanesi, 1999). This structure bends to insert into the plasma membrane and induce curvature before fission. In vitro dominant negative inhibition variants of the PH domain abolish phosphoinositide binding and knock out all synaptic vesicle reuptake (Lee et al., [1999](#mgg3362-bib-0008){ref-type="ref"}). Variants in the PH domain of dynamin 1 have been previously studied by Vallis et al. ([1999](#mgg3362-bib-0015){ref-type="ref"}) by creating a Lys535Ala mutant. The position Lys535 was chosen because it comes into proximity to the 5\'phosphate of the inositol ring in inositol‐1,4,5‐trisphosphate (IP3). The point mutation described in that article is at the same amino acid position as both patients in our study. While Patients 1 and 2 have a Lys535Glu variant, the mutated residue in that study is a Lys535Ala substitution. Each of these amino acid substitutions are significant because they do not share the same structure or chemical properties as lysine. Multiple PH domain mutants were compared, and while others did not show changed levels of transferrin uptake, a well‐established endocytosis assay, Lys535Ala showed inhibition of endocytosis and impairment of PIP2 binding (Vallis et al., [1999](#mgg3362-bib-0015){ref-type="ref"}). These findings support the critical role of Lys535 in the coordination of phosphoinositide binding, an essential step in endocytosis (Vallis et al., [1999](#mgg3362-bib-0015){ref-type="ref"}).

A similar study by Achiriloaie et al. ([2015](#mgg3362-bib-0005){ref-type="ref"}) compared PH domain variants K535M and K561M to a GTPase domain variant N272 (missing most of the GTPase domain) and wild‐type *DNM1*. The GTPase domain variant and K535M both inhibited endocytosis, while the K561 mutant and wild type *DNM1* showed no significant difference in endocytosis (Achiriloaie, Barylko, & Albanesi, 1999). This implies that not all amino acid substitutions in the PH domain are significant and reinforces the claim that Lys535 is essential to the PH loop binding to PIP2 and promoting endocytosis. PH domain mutations at other sites may not have a clinically discernable phenotype. We also examined whether the position of the pathogenic variants affects different isoforms of Dynamin 1, but found all variants involve all isoforms (Figure [2](#mgg3362-fig-0002){ref-type="fig"}b).

In summary, Dynamin 1 is mainly expressed in the central nervous system, explaining the neurological phenotype in *DNM1*‐related disorder. Previously reported patients carry pathogenic variants in the GTPase or middle domains and presented with epileptic encephalopathy and severe neurodevelopmental symptoms. Here, we report the first documented *DNM1* variant in the PH domain associated with a milder phenotype without epilepsy. Our data suggest a novel, possibly unique, and less severe phenotype resulting from a variant in the PH domain of dynamin 1. Reports of additional patients are needed to better define the genotype--phenotype correlation.
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